While there is no cure for psoriasis, an autoimmune skin disease, the science of psoriasis therapies is evolving at a very rapid pace. The recent Cosentyx® approval heralds a new era for psoriasis treatment at SkinCare Physicians’ Psoriasis Treatment Center near Boston.
Cosentyx® (secukinumab), a biologic therapy developed specifically for psoriasis, is now available for adults suffering from moderate-to-severe psoriasis. This is the first of several highly anticipated “second generation” biologics to complete rigorous testing and become available to treat this significant life-impacting disease.
Cosentyx® targets interleukin-17 (IL-17), one of the key chemical hormones that are elevated in people who have psoriasis. We now know that psoriasis is driven by underlying and excessive inflammation, and IL-17 is one of the critical entities involved in this process.
With this novel treatment, clear skin may now be a reality for patients suffering from psoriasis. In clinical trials, the success rate was astounding with over 70% of subjects achieving clearance or almost clearance of their psoriasis within 16 weeks. Common side effects included uncomplicated cold symptoms, headache and mild diarrhea.
Cosentyx® joins Enbrel®, Humira®, Stelara® and Remicade ® as biologic options for treating moderate-to-severe psoriasis. The addition of Cosentyx® to our psoriasis treatment armamentarium is a big win for patients still suffering from this disease. The odds are now exceedingly high that any patient who medically is a candidate for these therapies will find a treatment that works for them.
And the good news is that this is just the beginning. There are at least 4 other promising second generation biologic agents for psoriasis currently in their final stages of testing that may see approval in the next 1-3 years. It is an evolving and exciting time, and our Psoriasis Treatment Center in Boston has never been more equipped to help patients manage this disease.
Learn more about psoriasis:
Find Dr. Jeffrey Sobell on Google+